Utilization of circulating-tumor-cell (CTC) and cell free DNA (cfDNA) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease.

Inclusion Criteria:

• All subjects need to sign the informed consent form and age is above 20.
• Control group need to have mammogram /ultrasound results category1-3 and confirmed by PI.
• Cancer group subjects with pathology report confirmed to be malignant have not yet done surgery or treatment will be enrolled to the malignant group for analysis

Exclusion Criteria:

• Not willing to sign the informed consent form
• Have been undergone general anesthesia or regional anesthesia in 1 month
• Have been diagnosed with any type of cancer and been treated
• Have been suffering from autoimmune disorder such as SLE and RA
• Have been suffering from chronic infection such as IBD, pancreatitis, COPD or Interstitial pneumonia.
• Have been suffering from acute infection or other infectious diseases in 3 moths such as TB, pneumonia, urinary tract infection, or cellular infection
• Diagnosed with myelodysplastic syndrome or myeloproliferative diseases
• Other condition which may affect the CTC results, when determined by PI can be confirmed by other tests are if necessary

Breast cancer patients